Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH study (Biomarkers in ACute Heart Failure)

JACC: Heart Failure

Volumn 1, Issue 3, 2013, Pages 192-199

  Richards, Mark ^a,b   Di Somma, Salvatore ^c   Mueller, Christian ^d   Nowak, Richard ^e   Peacock, W Frank ^f   Ponikowski, Piotr ^g   Mockel, Martin ^h   Hogan, Christopher ⁱ   Wu, Alan H B ^j   Clopton, Paul ^k   Filippatos, Gerasimos S ^l   Anand, Inder ^m   Ng, Leong ⁿ   Daniels, Lori B ^o   Neath, Sean Xavier ^p   Shah, Kevin ^c,k   Christenson, Robert ^p   Hartmann, Oliver ^q   Anker, Stefan D ^h,r   Maisel, Alan ^o  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^l NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^m Veterans' Administration Minneapolis   (United States)

ⁿ UNIVERSITY OF LEICESTER   (United Kingdom)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF MARYLAND   (United States)

^q BRAHMS (part of Thermo Fisher Scientific)   (Germany)

^r IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

Atrial fibrillation; Heart failure; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; MID REGION AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSPNEA; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ATRIAL FIBRILLATION; HEART FAILURE; NATRIURETIC PEPTIDES;

ACUTE DISEASE; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 84878623090     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.02.004     Document Type: Article

References (34)

1. Li H., Easley A., Barrington W., Windle J. Evaluation and management of atrial fibrillation in the emergency department. Emerg Med Clin North Am 1998, 16:389-403.
2. Connors S., Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 1997, 13(Suppl A):19A-24A.
3. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001, 285:2370-2375.
4. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98:476-484.
5. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from comet. Eur Heart J 2005, 26:1303-1308.
6. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844.
7. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Utility of B-type peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
8. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006, 27:330-337.
9. Knudsen C.W., Omland T., Clopton P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2005, 46:838-844.
10. Morello A., Lloyd-Jones D.M., Chae C.U., et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007, 153:90-97.
11. Lee S.H., Jung J.H., Choi S.H., et al. Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 2006, 70:100-104.
12. Silvet H., Young-Xu Y., Walleigh D., et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003, 92:1124-1127.
13. Tsuchida K., Tanabe K. Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. J Cardiol 2004, 44:1-11.
14. Morgenthaler N.G., Struck J., Thomas B., Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236.
15. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2066.
16. von Haehling S., Jankowska E.A., Morgenthaler N.G., et al. Comparison of midregional pro-atrial natriuretic peptide with n-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1973-1980.
17. Gegenhuber A., Struck J., Poelz W., et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006, 52:827-831.
18. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007, 13:42-49.
19. Khan S.Q., O'Brien R.J., Struck J., et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007, 10:1525-1532.
20. Rienstra M., Van Gelder I.C., Van denBerg M.P., Boomsma F., Van Veldhuisen D. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 2006, 8:482-487.
21. Corell P., Gustafsson F., Kistorp C., Madsen L.H., Schou M., Hildebrandt P. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 2007, 117:395-402.
22. Mookherjee S., Anderson G., Smulyan H., Vardan S. Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am J Cardiol 1991, 67:377-380.
23. Nishino N., Hoshida S., Tanouchi J., et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000, 85:1451-1454.
24. Ohta Y., Shimada T., Yoshitomi H., et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001, 17:415-420.
25. Vinch C.S., Rashkin J., Logsetty G., et al. Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology 2004, 102:188-193.
26. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
27. Van Den Berg M.P., Tuinenburg A.E., Crijns H.J.G.M., Van Gelder I.C., Gosselink A.T.M., Lie K.I. Heart failure and atrial fibrillation: current concepts and controversies. Heart 1997, 77:309-313.
28. Naito M., David D., Michelson E.L., Schaffenburg M., Dreifus L.S. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983, 106:284-291.
29. Inoue S., Murakami Y., Sano K., et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000, 6:92-96.
30. Kambayashi Y., Nakao K., Mukoyama M., et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990, 259:341-345.
31. Doyama K., Fukuomoto M., Takemura G., et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol 1998, 32:1832-1838.
32. Edwards B.S., Zimmerman R.S., Schwab T.R., Heublein D.M., Burnett J.C. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988, 62:191-195.
33. Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96:1180-1184.
34. Tuinenburg A.E., Brundel B.J., Van Gelder I.C., et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999, 10:827-835.